Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (4) , 165.e9-165.e15
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer CommitteeThe Korean Journal of Internal Medicine, 2018
- Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal CancerChemotherapy, 2014
- Preoperative Accuracy of Diagnostic Evaluation of the Urachal MassJournal of Urology, 2013
- The Clinical Epidemiology of Urachal Carcinoma: Results of a Large, Population Based StudyJournal of Urology, 2012
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- Urothelial Carcinoma Versus Squamous Cell Carcinoma of Bladder: Is Survival Different With Stage Adjustment?Urology, 2009
- Predictors of survival from urachal cancerCancer, 2007
- Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancyCancer, 2006
- Population Based Survival Data on Urachal TumorsJournal of Urology, 2006
- Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center ExperienceJournal of Urology, 2003